Helena Guedes

Can we combine radiotherapy with CDK4/6i, HER2, PARP or mTOR targeted agents? Just out on the green journal the ESMO-ESTRO systematic review (107 studies) and Delphi consensus on the topic. Huge work, masterfully led by Evert van Aken. Read it here: thegreenjournal.com/article/S0167-…

We now have more data on adj CDK4/6i at #ESMO25 + we’ll continue to use these Rx in metastatic settings as well. This is the table we’ve used (AEs + doses) for #Ribociclib #Abemaciclib, + #Palbociclib w/ @DrSGraff for our #ToxCheck 🗣️ #bcsm #OncTwitter @OncoAlert @OncUpdates

ESMO HANDBOOK OF CANCER GENETICS AND GENOMICS #ESMO25 List of Actionable Genes and the FDA-approved Molecularly Matched Drugs👇

With the final analysis of the last of the 1st line metastatic clear cell RCC trials combination trials it’s still fair to say ‘pick one and use it well’. #GUARDSymposium2025 Ipi/nivo is less good at getting initial control but has less long term toxicity. @brian_rini @OncoAlert

Axillary Management After Neoadjuvant Systemic Therapy From Dr. Mediget Teshome's wonderful presentation👇 #ASCO25

🚨 Exercise is no longer optional, it is essential! One of the most impactful studies at #ASCO25 🏃‍♂️ The #CHALLENGE trial (LBA4319) proves that structured exercise after chemo in stage III colon cancer is not just lifestyle—it’s life-saving. 📊 5y DFS: 80.3% vs 73.9% ❤️ 8y OS: 90.3% vs 83.2% 📉 Mortality risk ↓ by 37% 📄 Simultaneously in @NEJM nejm.org/doi/full/10.10… #ColorectalCancer #OncoTwitter #ExerciseOncology #exercise

🎓 SAVE THE DATE | 26.09.2025 📍 Hotel NH Coimbra Dona Inês Está de volta o CIPOG – Curso de Introdução aos Princípios da Oncologia Geriátrica, na sua 3.ª edição! 📚 Organizado pelo #GTOG – Grupo de Trabalho de Oncologia Geriátrica - da @SociedadeSpo

Excellent summary slides for current evidence for pancreatic cancer treatment . Useful for quick reference. @asco #asco25 taken from talk by Dr Brian Wolpin 👍@OncoAlert @brunolarvol

⚡️ Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice #BladderCancer @NatRevClinOncol nature.com/articles/s4157…

Muito obrigada ao NIJE pelo convite para falar sobre “O papel das sociedades científicas durante o internato” no 1.º ENIO - Encontro Nacional de Internos de Oncologia! 👏🧠💬 #Oncologia #InternatoMédico #SociedadesCientíficas #SPO #NIJE #ENIO

RWE is crucial for our daily clinical practice! What insightful discussions on mUC treatments! Balancing QoL with efficacy is the key! @drenriquegrande @DavidBenjaminMD

🔥EASL Clinical Practice Guidelines on the management of extrahepatic cholangiocarcinoma🔥 @JHepatology doi.org/10.1016/j.jhep… 👉get the lastest update on the diagnosis and management of eCCA @myESMO @EASLedu @ILCAnews #livertwitter

Detach..

Lines of Therapy for Locally Advanced/Metastatic Urothelial Carcinoma: The New Paradigm 🌟 ascopubs.org/doi/pdf/10.120… @JCOOP_ASCO

Terapêuticas de Suporte em Oncologia nos #encontrosdaprimavera2025. Moderado pela Prof. Claudia Vieira e Prof. Ana Joaquim. “Exercício Físico na Prevenção e no tratamento Oncológico “ pelo Prof. Alberto Alves. Tive o prazer de abordar o tema “ Guidelines de Emese:revisão crítica”

📘Hepatitis B reactivation prophylaxis during immunosupressive treatments AGA 2025 Guideline 🔵In HbsAg ➖, antiHbc ➕ 🚨Anthracyclines, TKIs, TACE and steroids (mod/high dose, >4weeks) ➡️ moderate risk❗️ 👉doi.org/10.1053/j.gast… @OncoAlert @myESMO @ASCO @EORTC @CancerCareMASCC #cancer #oncology #MedX

Just published in @JCO_ASCO the updated @ASCO guidelines on fertility preservation in people with #cancer: a must read for all colleagues involved in cancer care to increase awareness on #oncofertility issues @OncoAlert @AnnPartridgeMD @oncofertility Link: ascopubs.org/doi/10.1200/JC…

The 19th St. Gallen Conference took place this week in Vienna. Nearly 80 expert panelists voted on key debated topics in breast oncology, selected by @DrHBurstein & @curijoey. Here’s 10 key results from the #SGBCC2025 consensus voting, divided by topic/breast cancer subtype.

Management of immune checkpoint inhibitor-associated toxicities in older adults with cancer: recommendations from the International Society of Geriatric Oncology (SIOG) #CancerHasNoAge 🚨 buff.ly/lg73Tsp Immune checkpoint inhibitors (ICIs) have significantly improved cancer treatment, particularly for older adults, a rapidly growing demographic often prescribed these therapies. However, managing ICI-related toxicities in older adults, especially those with frailty and comorbidities, presents unique challenges. This Policy Review, developed by the International Society of Geriatric Oncology (SIOG), provides an evidence-based framework for healthcare providers, caregivers, and policymakers, addressing specific considerations for older adults that are not sufficiently covered by existing guidelines, while integrating geriatric oncology principles into the treatment approach. #GeriOnc #Immunotherapy @CEochagain @neuendorff_nr @jleipy @martheverhaert @NienkedeGlas @kgsindhu @FabioGomes_Go @Decoster_Lore @SRostoft @nicolobattisti #OncoAlertAF @nataliagandur @acampsmalea @BiagioRicciutMD @yekeduz_emre @HHorinouchi @FadiHaddad_MD @Dr_Ivanoncologo @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK Ping GeriOnc Faculty @WilliamDale_MD @IshwariaMD @drcbsteer @ravikanesvaran @crisbergerot